Kwang Dong Pharmaceutical Co., Ltd. (KRX:009290)
South Korea · Delayed Price · Currency is KRW 6,310.00
-120.00 (-1.87%)
Last updated: Sep 2, 2026, 2:34 PM KST
Kwang Dong Pharmaceutical Ratios and Metrics
Market cap in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 2, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 235,721 | 230,184 | 218,039 | 297,799 | 244,840 | 305,229 | |
Market Cap Growth | 0.02% | 5.57% | -26.78% | 21.63% | -19.79% | -27.51% |
Enterprise Value | 425,280 | 343,552 | 335,136 | 283,794 | 196,173 | 300,829 |
Last Close Price | 6430.00 | 5792.49 | 5278.48 | 7209.39 | 5705.21 | 6995.77 |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 2, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PE Ratio | 13.44 | 10.98 | 5.39 | 8.06 | 10.13 | 12.71 |
Forward PE | - | 14.32 | 14.32 | 14.32 | 14.32 | 14.32 |
PS Ratio | 0.14 | 0.14 | 0.13 | 0.20 | 0.17 | 0.23 |
PB Ratio | 0.33 | 0.32 | 0.35 | 0.51 | 0.45 | 0.58 |
P/TBV Ratio | 0.41 | 0.38 | 0.40 | 0.59 | 0.49 | 0.63 |
P/FCF Ratio | 230.64 | 4.39 | - | - | 6.54 | 9.80 |
P/OCF Ratio | 13.33 | 2.80 | - | - | 3.90 | 5.56 |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 2, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
EV/Sales Ratio | 0.25 | 0.21 | 0.20 | 0.19 | 0.14 | 0.23 |
EV/EBITDA Ratio | 8.89 | 7.00 | 7.51 | 5.16 | 3.75 | 5.10 |
EV/EBIT Ratio | 15.56 | 11.07 | 11.14 | 6.75 | 5.13 | 6.70 |
EV/FCF Ratio | 416.11 | 6.55 | - | - | 5.24 | 9.66 |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 2, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Debt / Equity Ratio | 0.43 | 0.43 | 0.46 | 0.40 | 0.25 | 0.25 |
Debt / EBITDA Ratio | 5.57 | 6.18 | 6.41 | 4.29 | 2.64 | 2.24 |
Debt / FCF Ratio | 294.44 | 5.78 | - | - | 3.69 | 4.24 |
Net Debt / Equity Ratio | 0.18 | 0.11 | 0.20 | 0.05 | -0.13 | -0.11 |
Net Debt / EBITDA Ratio | 2.28 | 1.54 | 2.70 | 0.54 | -1.35 | -0.94 |
Net Debt / FCF Ratio | 120.57 | 1.44 | -1.37 | -0.63 | -1.89 | -1.79 |
Asset Turnover | 1.37 | 1.33 | 1.46 | 1.51 | 1.58 | 1.56 |
Inventory Turnover | 6.78 | 6.47 | 6.62 | 6.95 | 7.34 | 6.58 |
Quick Ratio | 0.90 | 0.97 | 0.95 | 1.03 | 1.23 | 1.32 |
Current Ratio | 1.34 | 1.37 | 1.55 | 1.46 | 1.71 | 1.81 |
Return on Equity (ROE) | 3.46% | 3.21% | 6.94% | 6.94% | 4.97% | 4.96% |
Return on Assets (ROA) | 1.68% | 1.56% | 1.67% | 2.62% | 2.63% | 3.28% |
Return on Invested Capital (ROIC) | 2.82% | 2.80% | 3.24% | 6.18% | 5.94% | 7.16% |
Return on Capital Employed (ROCE) | 4.30% | 3.90% | 4.20% | 6.80% | 6.60% | 8.00% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 2, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Earnings Yield | 9.26% | 9.11% | 18.57% | 12.41% | 9.87% | 7.87% |
FCF Yield | 0.43% | 22.80% | -40.31% | -15.62% | 15.29% | 10.20% |
Dividend Yield | 1.67% | - | - | - | 1.75% | 1.43% |
Payout Ratio | 22.76% | 18.73% | 9.90% | 11.11% | 16.99% | 17.10% |
Buyback Yield / Dilution | -14.97% | -0.50% | 1.06% | 1.48% | 0.11% | -1.48% |
Total Shareholder Return | -13.30% | -0.50% | 1.06% | 1.48% | 1.87% | -0.05% |